sees fy adjusted earnings per diluted share $num-one to $2.00 from continuing operations.
sees fy adjusted earnings per share $num-one to $num - two.
qtr-three adjusted earnings per share $num-two.
sees qtr-four adjusted earnings per diluted share accretion of approximately $num-one.
sees fy adjusted earnings per diluted share $num-one to $8.00 excluding items.
qtr-three adjusted earnings per share $num-one.
qtr-three adjusted earnings per share $num-one.
sees fy year-six adjusted earnings per share $num-one to $num-$num-two.
sees fy year-seven share repurchases of approximately $num-one billion.
sees fy year-seven adjusted earnings per share $num-one.
sees qtr-one international segment adjusted earnings per diluted share accretion of $num-one.
sees fy year-six adjusted operating profit growth of num-three% to num-four%.
sees u.s. pharmaceutical segment revenue to increase num-one% to num-two% in year-six.
sees fy year-six adjusted earnings per share $num-one to $num - two from continuing operations.
expect to execute share repurchases of up to $num-one billion in qtr-four of year-six.
qtrly gaap loss per share $num-one million.
